WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has unveiled groundbreaking results from the CLEAR study, the first head-to-head randomized controlled trial comparing the UroLift™ System with Rezūm™ ...
Teleflex announces favorable results for UroLift™ in treating BPH, showing higher patient satisfaction and better early recovery compared to Rezūm. Teleflex Incorporated announced new results from the ...
Teleflex TFX recently announced the upcoming full market release of the Advanced Tissue Control (“ATC”) feature on its unified UroLift 2 System — a platformdesigned for the treatment of benign ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback